Author

Marguerite Fournier

Institutions: The Lymphoma Academic Research Organisation, Hôpital Lyon Sud

Observed institutions: The Lymphoma Academic Research Organisation, Hôpital Lyon Sud, Lymphoma Study Association

ORCID: 0009-0000-3311-4782

Observed ORCID: 0009-0000-3311-4782

OpenAlex ID: A5065275609

Toward A Serious Game to Help Future Military Doctors Face Mass Casualty Incidents

2023 · Henri de Lesquen, Raphael Paris, et al. · Journal of Special Operations Medicine · 9

The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients

2023 · Hervé Ghesquières, Daphné Krzisch, et al. · Blood · 6

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma

2025 · Matthew J. Maurer, Vit K. Prochazka, et al. · Journal of Clinical Oncology · 5

Personalized baseline and residual TMTV influence treatment response and outcomes in relapsed/refractory lymphomas: results from the GATA study

2025 · Solène Malmon, Olivier Casasnovas, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2

Final Analysis of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA) Using Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Patients over 60 Years with Advanced-Stage Classical Hodgkin Lymphoma

2021 · Herve Ghesquieres, Rene-Olivier Casasnovas, et al. · Blood · 2

Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study

2026 · Julien Lazarovici, Sandy Amorim, et al. · Haematologica

Center effect on large B-cell lymphoma outcome in frontline prospective Phase II and III trials : A lysa study

2025 · Tristan Robert-Van Houtteghem, Marguerite Fournier, et al. · Blood

Valemetostat monotherapy in patients with relapsed or refractory B-cell lymphoma: Final results of the Phase 2 valym study from the lysa

2025 · Emmanuel Bachy, Fontanet Bijou, et al. · Blood

Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

2024 · Yannick Le Bris, Barbara Burroni, et al. · Blood

Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase 2 Valym Study from the Lysa

2024 · Emmanuel Bachy, Bernard Drenou, et al. · Blood

Precautions to Consider in the Analysis of Prognostic and Predictive Indices

2024 · Loïc Chartier, Aurélien Belot, et al. · Journal of Nuclear Medicine

Assessing predictive abilities of hazard-based regression models for survival data: a tutorial for prognosis modelling

2024 · Marguerite Fournier, Francisco Javier Rubio, et al. · Research Square

CD20low/CD68high a Promising Microenvironnement Profile Identifying Classical Hodgkin Lymphoma Patients with Poor Outcome a Lysa Study

2023 · Alexandra Traverse-Glehen, Laurent Martin, et al. · Blood

Works count: 13

Citation count: 23

H-index: 3

I10-index: